Your Partner for cGMP Biologics Manufacturing
With nearly 30 years of expert experience in cell culture, Biovest will formulate the optimal strategy for your biologics manufacturing. By accurately matching the level of hollow-fiber production technology to your Phase of product development, our clients can manage their overall investment risk. Only as products advance to the next stage of development does Biovest scale to a higher-output production tool.
With our focus on pre-launch therapeutics and marketed diagnostics production, Biovest serves all the manufacturing needs of our clients. From process development to regulatory support, our one-stop comprehensive approach provides solutions for clients that have chosen to temporarily or permanently outsource any or all stages of drug development.
Hollow Fiber = Higher Cell Densities
Our patented hollow fiber technology is the key to optimizing your biologics manufacturing. For Phase I, Phase II and Phase III cGMP production, our hollow fiber bioreactor perfusion technology provides economic advantages through largely automated culture of a relatively large, densely packed population of cells in a small space. Additionally, the low molecular weight cut-off of the fiber membrane allows more expensive media components to be conserved, while less expensive basal media is continuously perfused through the bioreactor. As a result, this automated approach can be more cost-effective than conventional platforms generally used for maintenance of large cell populations.
If needed, commercial production capacity for product launch is seamless, as Biovest provides all the required regulatory support, including biocompatibility studies.
Hollow fiber systems provide a compact, efficient, stable and economic method of producing biologics